ConductScience.org, home

Paper15054565

Identification of cytochromes P450 2C9 and 3A4 as the major catalysts of phenprocoumon hydroxylation in vitro.

Ufer M and 5 others. Eur J Clin Pharmacol, 2004. Cited by 61 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Identification of cytochromes P450 2C9 and 3A4 as the major catalysts of phenprocoumon hydroxylation in vitro. Papers, record 15054565. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/15054565

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Identification of cytochromes P450 2C9 and 3A4 as the major catalysts of phenprocoumon hydroxylation in vitro.
PubMed
Journal
Eur J Clin Pharmacol
PubMed
Year
2004
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
61
iCite
Relative citation ratio, by iCite
1.9
iCite
Revised in PubMed
2018-12-11
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Ufer MMike
2Svensson JOJan O
3Krausz KWKristopher W
4Gelboin HVHarry V
5Rane AAnders
6Tybring GGunnel

Source PubMed

Topics22

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Aryl Hydrocarbon HydroxylasesMajor topic
Cytochrome P-450 Enzyme SystemMajor topic
HydroxylationMajor topic
PhenprocoumonMajor topic
Antibodies, Monoclonal
Anticoagulants
Biotransformation
Catalysis
Cytochrome P-450 CYP2C19
Cytochrome P-450 CYP2C8
Cytochrome P-450 CYP2C9
Cytochrome P-450 CYP3A
Drug Therapy, Combination
Enzyme Inhibitors
Forecasting
Gene Expression
Humans
Isomerism
Microsomes, Liver
Mixed Function Oxygenases
Recombinant Proteins
Troleandomycin

Source PubMed

References42

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
110,771,452Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions.Br J Clin Pharmacol2000https://conductscience.org/library/papers/10771452PubMed
28,723,744Formation of (R)-8-hydroxywarfarin in human liver microsomes. A new metabolic marker for the (S)-mephenytoin hydroxylase, P4502C19.Drug Metab Dispos1996https://conductscience.org/library/papers/8723744PubMed
310,821,163Assessment of specificity of eight chemical inhibitors using cDNA-expressed cytochromes P450.Xenobiotica2000https://conductscience.org/library/papers/10821163PubMed
42,229,265Determination of the plasma protein binding of the coumarin anticoagulants phenprocoumon and its metabolites, warfarin and acenocoumarol, by ultrafiltration and high-performance liquid chromatography.J Chromatogr1990https://conductscience.org/library/papers/2229265PubMed
514,209,971THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. I. EVIDENCE FOR ITS HEMOPROTEIN NATURE.J Biol Chem1964https://conductscience.org/library/papers/14209971PubMed
611,157,645Hemorrhagic complications of anticoagulant treatment.Chest2001https://conductscience.org/library/papers/11157645PubMed
78,873,220The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism.Pharmacogenetics1996https://conductscience.org/library/papers/8873220PubMed
87,773,301Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese.Pharmacogenetics1995https://conductscience.org/library/papers/7773301PubMed
99,526,963Warfarin analog inhibition of human CYP2C9-catalyzed S-warfarin 7-hydroxylation.Thromb Res1997https://conductscience.org/library/papers/9526963PubMed
1011,038,154Cytochrome P4502C9 is the principal catalyst of racemic acenocoumarol hydroxylation reactions in human liver microsomes.Drug Metab Dispos2000https://conductscience.org/library/papers/11038154PubMed
119,920,790Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population.Biochem Biophys Res Commun1999https://conductscience.org/library/papers/9920790PubMed
123,490,277The in vivo effects of acenocoumarol, phenprocoumon and warfarin on vitamin K epoxide reductase and vitamin K-dependent carboxylase in various tissues of the rat.Biochim Biophys Acta1986https://conductscience.org/library/papers/3490277PubMed
13388,439Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.Proc Natl Acad Sci U S A1979https://conductscience.org/library/papers/388439PubMed
148,365,690Concentrations of phenprocoumon in serum and serum water determined by high-performance liquid chromatography in patients on oral anticoagulant therapy.Haemostasis1993https://conductscience.org/library/papers/8365690PubMed
1512,487,725In vitro identification of metabolic pathways and cytochrome P450 enzymes involved in the metabolism of etoperidone.Xenobiotica2002https://conductscience.org/library/papers/12487725PubMed
167,720,520Cytochrome P450 inhibitors. Evaluation of specificities in the in vitrometabolism of therapeutic agents by human liver microsomes.Drug Metab Dispos1995https://conductscience.org/library/papers/7720520PubMed
179,822,057Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range.Chest1998https://conductscience.org/library/papers/9822057PubMed
1815,128,047Effects of CYP2C9 polymorphisms on the pharmacokinetics of R- and S-phenprocoumon in healthy volunteers.Pharmacogenetics2004https://conductscience.org/library/papers/15128047PubMed
193,621,786The effect of sulfinpyrazone on the disposition of pseudoracemic phenprocoumon in humans.Clin Pharmacol Ther1987https://conductscience.org/library/papers/3621786PubMed
2010,793,325Inhibition of phenprocoumon anticoagulation by carbamazepine.Eur Neuropsychopharmacol2000https://conductscience.org/library/papers/10793325PubMed

See all 42 references

Cited by19

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 61 citations.

PMIDTitleJournalYearIn PapersSource
36,208,621Selective Serotonin Reuptake Inhibitor Use and Risk of Major Bleeding during Treatment with Vitamin K Antagonists: Results of A Cohort Study.Thromb Haemost2023https://conductscience.org/library/papers/36208621PubMed
33,638,977The role of pharmacogenomics in contemporary cardiovascular therapy: a position statement from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy.Eur Heart J Cardiovasc Pharmacother2022https://conductscience.org/library/papers/33638977PubMed
31,835,701Influence of Selected Carbon Nanostructures on the CYP2C9 Enzyme of the P450 Cytochrome.Materials (Basel)2019https://conductscience.org/library/papers/31835701PubMed
30,830,337Targeted and global pharmacometabolomics in everolimus-based immunosuppression: association of co-medication and lysophosphatidylcholines with dose requirement.Metabolomics2017https://conductscience.org/library/papers/30830337PubMed
29,283,396Pharmacogenomics of CYP2C9: Functional and Clinical Considerations.J Pers Med2017https://conductscience.org/library/papers/29283396PubMed
24,324,947VKORC1 and CYP2C9 Genotype Variations in Relation to Warfarin Dosing in Korean Stroke Patients.J Stroke2013https://conductscience.org/library/papers/24324947PubMed
23,919,835Pharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumon.Br J Clin Pharmacol2014https://conductscience.org/library/papers/23919835PubMed
23,673,224Predicting CYP2C19 catalytic parameters for enantioselective oxidations using artificial neural networks and a chirality code.Bioorg Med Chem2013https://conductscience.org/library/papers/23673224PubMed
23,519,598Quantifying the effect of covariates on concentrations and effects of steady-state phenprocoumon using a population pharmacokinetic/pharmacodynamic model.Clin Pharmacokinet2013https://conductscience.org/library/papers/23519598PubMed
21,452,031Drug interactions with phenprocoumon and the risk of serious haemorrhage: a nested case-control study in a large population-based German database.Eur J Clin Pharmacol2011https://conductscience.org/library/papers/21452031PubMed
21,110,013Prediction of phenprocoumon maintenance dose and phenprocoumon plasma concentration by genetic and non-genetic parameters.Eur J Clin Pharmacol2011https://conductscience.org/library/papers/21110013PubMed
20,981,234Pharmacogenetics of anticoagulants.Hum Genomics Proteomics2010https://conductscience.org/library/papers/20981234PubMed
19,641,912Evidence for immunological (allergic) mechanisms in a subgroup of patients with phenprocoumon-induced liver disease.Eur J Clin Pharmacol2009https://conductscience.org/library/papers/19641912PubMed
19,082,874Prediction of the effects of genetic polymorphism on the pharmacokinetics of CYP2C9 substrates from in vitro data.Pharm Res2009https://conductscience.org/library/papers/19082874PubMed
18,758,764Evidence for a pharmacogenetic adapted dose of oral anticoagulant in routine medical practice.Eur J Clin Pharmacol2008https://conductscience.org/library/papers/18758764PubMed
18,698,879Pharmacogenetics of oral anticoagulants: a basis for dose individualization.Clin Pharmacokinet2008https://conductscience.org/library/papers/18698879PubMed
17,318,526Coumarin anticoagulants and co-trimoxazole: avoid the combination rather than manage the interaction.Eur J Clin Pharmacol2007https://conductscience.org/library/papers/17318526PubMed
16,847,664Obesity is associated with a slower response to initial phenprocoumon therapy whereas CYP2C9 genotypes are not.Eur J Clin Pharmacol2006https://conductscience.org/library/papers/16847664PubMed
16,372,822Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol.Clin Pharmacokinet2005https://conductscience.org/library/papers/16372822PubMed

Genes7

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CYP19A11,588PubTator's text mininghttps://conductscience.org/library/genes/1588NCBI Gene
CYP2C181,562PubTator's text mininghttps://conductscience.org/library/genes/1562NCBI Gene
CYP2C191,557PubTator's text mininghttps://conductscience.org/library/genes/1557NCBI Gene
CYP2C81,558PubTator's text mininghttps://conductscience.org/library/genes/1558NCBI Gene
CYP2C91,559PubTator's text mininghttps://conductscience.org/library/genes/1559NCBI Gene
CYP3A41,576PubTator's text mininghttps://conductscience.org/library/genes/1576NCBI Gene
CYP4F34,051PubTator's text mininghttps://conductscience.org/library/genes/4051NCBI Gene

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/15054565

GET https://conductscience.org/api/papers/v1/15054565/references?page=2